Back to search
FDAFDA · Food and drugs·Recall number D-0105-2025

Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60

Published December 11, 2024 · Recall initiated: November 19, 2024

Summary

FDA records drug Class II recall D-0105-2025, published December 11, 2024 and initiated November 19, 2024. Recalling firm: Rising Pharma Holding, Inc.; Status: Ongoing; Reported quantity: 209,376 bottles; Lot: a) Lot # DT2022023A, DT2022024A, DT2022025A, DT2022026A, DT2022027A, exp. date Nov-24 DT2023001B, DT2023004A, DT2023005A, DT2023006A, exp. date Jan-25. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Rising Pharma Holding, Inc.
Distributor
Nationwide.
Lot
a) Lot # DT2022023A, DT2022024A, DT2022025A, DT2022026A, DT2022027A, exp. date Nov-24 DT2023001B, DT2023004A, DT2023005A, DT2023006A, exp. date Jan-25
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ NDC 57237-017-60 recalled?

Yes. FDA published recall D-0105-2025 on December 11, 2024. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit

What should I do if I have this product?

Voluntary: Firm initiated · Letter